SMS Lifesciences India Ltd's Q3FY25 Quarter Results
- 13 Feb 2025
Result Summary
- SMS Lifesciences India Ltd reported a 5.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 16.5%.
- Its expenses for the quarter were up by 2.6% QoQ and 13.0% YoY.
- The net profit increased 47.3% QoQ and increased 18.0% YoY.
- The earnings per share (EPS) of SMS Lifesciences India Ltd stood at 18.1 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 84.66 | 80.50 | 72.64 | 5.2% | 16.5% |
Total Expenses | 77.75 | 75.80 | 68.83 | 2.6% | 13.0% |
Profit Before Tax | 6.92 | 4.70 | 3.81 | 47.2% | 81.6% |
Tax | 2.06 | 1.40 | -0.31 | 47.1% | -764.5% |
Profit After Tax | 4.86 | 3.30 | 4.12 | 47.3% | 18.0% |
Earnings Per Share | 18.10 | 15.50 | 14.20 | 16.8% | 27.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
SMS Lifesciences India Ltd is a pharmaceutical company that primarily focuses on the manufacturing of active pharmaceutical ingredients (APIs). The company operates within the pharmaceutical industry, and its product offerings are integral to the production of various medications. Recent major developments may include expansions in production capacity or strategic partnerships, although specific details are not available in the provided data. SMS Lifesciences serves a wide range of customers within the healthcare sector, ensuring the supply of essential components for drug manufacturing.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), SMS Lifesciences India Ltd reported a total income of ₹84.66 crores. This marks a quarter-over-quarter (QoQ) increase of 5.2% from ₹80.50 crores in the second quarter of the fiscal year 2025 (Q2FY25). Year-over-year (YoY), the revenue increased by 16.5% compared to ₹72.64 crores in the third quarter of the fiscal year 2024 (Q3FY24). This data indicates a consistent growth trend in the company's revenue over the specified periods.
Profitability
The company's profitability metrics for Q3FY25 show a profit before tax of ₹6.92 crores, which is a 47.2% increase QoQ from ₹4.70 crores in Q2FY25. When compared to Q3FY24, where the profit before tax was ₹3.81 crores, there is an 81.6% YoY increase. The tax expense for Q3FY25 was ₹2.06 crores, reflecting a 47.1% rise QoQ from ₹1.40 crores in Q2FY25. Notably, the tax expense in Q3FY24 was a negative ₹0.31 crores. The company reported a profit after tax of ₹4.86 crores for Q3FY25, representing a 47.3% QoQ increase from ₹3.30 crores in Q2FY25 and an 18.0% YoY increase from ₹4.12 crores in Q3FY24.
Operating Metrics
Earnings per share (EPS) for SMS Lifesciences in Q3FY25 was ₹18.10, showing a QoQ growth of 16.8% from ₹15.50 in Q2FY25. Compared to Q3FY24, the EPS increased by 27.5% from ₹14.20. This growth in EPS reflects the company's improved financial performance over the respective periods. The total expenses for Q3FY25 were reported at ₹77.75 crores, which is an increase of 2.6% QoQ from ₹75.80 crores in Q2FY25 and a 13.0% YoY increase from ₹68.83 crores in Q3FY24. These metrics indicate the company's increasing operational costs alongside its revenue growth.
